Danny Deckard
Medical · Dallas, TXNPI 1386973451
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,828 of the $100,648 with a category attached, or 73.4%. 36 manufacturers reported payments, led by Viiv Healthcare Company at 38.4% of the total. Reporting peaked in 2023 at $48,042 and has fallen 91.7% since, to $4,009 in 2024. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 443 payments — averaging $227.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$39K
- Gilead$36K
- EMD Serono, Inc.$8K
- Merck$8K
- Janssen Scientific Affairs, LLC$6K
- Janssen Products, LP$1K
- plus $3K from 30 others
What the payments were for
- Consulting fees$4,1904%
- Speaking & faculty fees$73,82873%
- Travel & lodging$14,61815%
- Food & beverage$7,8968%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 145 | $38,637 |
| Gilead | 134 | $36,419 |
| EMD Serono, Inc. | 18 | $8,174 |
| Merck | 27 | $7,862 |
| Janssen Scientific Affairs, LLC | 6 | $5,714 |
| Janssen Products, LP | 3 | $1,156 |
| Theratechnologies Inc. | 9 | $919 |
| Novo Nordisk | 24 | $279 |
| Johnson & Johnson(2 entities) | 16 | $244 |
| AstraZeneca | 4 | $163 |
| Napo Pharmaceuticals Inc | 7 | $142 |
| AbbVie | 8 | $139 |
| Lilly USA, LLC | 7 | $108 |
| Antares Pharma, Inc. | 6 | $96 |
| Biohaven Pharmaceuticals, Inc. | 1 | $76 |
| Amgen | 2 | $49 |
| GSK | 3 | $47 |
| Lundbeck LLC | 2 | $41 |
| Eisai Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Pfizer | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Pylant Medical | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Abbott | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$100,648 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 21 | $84,288 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $36,750 |
| Atorvastatin Calcium | 34 | $353 |
| Trazodone Hcl | 34 | $279 |
| Bupropion XlBupropion Hcl | 12 | $260 |
| Mirtazapine | 12 | $173 |
| Rosuvastatin Calcium | 13 | $151 |
| Anastrozole | 12 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $36,419 | $121,03836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.
Other medical in Dallas
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Janine ShinnDallas$84K
- Andrew GarzaDallas$43K
- Alyssa SpiegelDallas$18K
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Shakira CabreraSan Antonio$116K
- Courtney AldridgeSan Antonio$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.